Related Experiment Video
Updated: Oct 12, 2025
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy
Suresh Victor1, Eridan Rocha-Ferreira2, Ahad Rahim3
1Centre for the Developing Brain, Department of Perinatal Imaging and Health, School of Biomedical Engineering and Imaging Sciences, King's College London, 1st Floor, South Wing, St Thomas' Hospital, Westmister Bridge Road, London, UK. suresh.victor@kcl.ac.uk.
Insights
New pharmacological therapies, including erythropoietin and allopurinol, show promise for improving outcomes in neonatal hypoxic-ischemic encephalopathy (HIE) beyond therapeutic hypothermia. Further research and clinical trials are crucial to address global challenges and optimize treatment strategies for HIE.
Area of Science:
- Neonatal neurology
- Neurocritical care
- Pharmacology
Background:
- Hypoxic-ischemic encephalopathy (HIE) affects 0.75 million babies globally each year, causing significant neurodevelopmental impairment.
- Therapeutic hypothermia (TH) is a standard HIE treatment but has limited efficacy, with 48% experiencing death or disability.
- There is a critical need for additional therapies to improve HIE outcomes, especially in low- and middle-income countries.
Purpose of the Study:
- To review promising pharmacological treatments for neonatal HIE that can be used in conjunction with therapeutic hypothermia.
- To identify key challenges and future directions for HIE research and clinical implementation.
Main Methods:
- Review of current literature on pharmacological interventions for neonatal HIE.
- Focus on agents like erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4/exenatide.
- Analysis of ongoing clinical trials and identified research gaps.
Main Results:
- Erythropoietin and allopurinol demonstrate significant promise and are advancing to Phase 3 clinical trials.
- Melatonin, cannabidiol, and exendin-4/exenatide also show potential as adjunctive HIE therapies.
- Current treatments, including TH, still result in substantial adverse outcomes, highlighting the need for novel approaches.
Conclusions:
- Pharmacological agents offer a promising avenue to enhance HIE treatment beyond therapeutic hypothermia.
- Optimal animal models, increased industry support, juvenile toxicology studies, and robust clinical trials are essential for future progress.
- Addressing global challenges is critical to translate promising therapies into effective clinical practice for HIE.
Abstract:
Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associated with 2.4% of the total Global Burden of Disease. Therapeutic hypothermia (TH), a treatment that is now standard of care in high-income countries, provides proof of concept that strategies that aim to improve neurodevelopment are not only possible but can also be implemented to clinical practice. While TH is beneficial, neonates with moderate or severe HIE treated with TH still experience devastating complications: 48% (range: 44-53) combined death or moderate/severe disability. There is a concern that TH may not be effective in low- and middle-income countries. Therapies that further improve outcomes are desperately needed, and in high-income countries, they must be tested in conjunction with TH. We have in this review focussed on pharmacological treatment options (e.g. erythropoietin, allopurinol, melatonin, cannabidiol, exendin-4/exenatide). Erythropoietin and allopurinol show promise and are progressing towards the clinic with ongoing definitive phase 3 randomised placebo-controlled trials. However, there remain global challenges for the next decade. Conclusion: There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials to avoid exposure to harmful medications or abandoning putative treatments. What is Known: • Therapeutic hypothermia is beneficial in neonatal hypoxic-ischemic encephalopathy. • Neonates with moderate or severe hypoxic-ischemic encephalopathy treated with therapeutic hypothermia still experience severe sequelae. What is New: • Erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4/exenatide show promise in conjunction with therapeutic hypothermia. • There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials.
